"Fifteen percent will have some problem with the first drug that will lead to discontinuation and a different drug," Dr. Hauser added.
Nausea was the most common symptom that led to discontinuation.
Headache and weight gain frequently led to discontinuation.
Time to discontinuation was assessed for each OMPM and compared using Cox regression models.
This withdrawal flare phenomenon has not been thoroughly investigated subsequent to discontinuation of anti-angiogenic therapy.
All adverse reactions were graded as mild or moderate, and none led to discontinuation of study.
This lead to discontinuation of the trial program for these molecules [15, 25].
Five subjects experienced a total of 10 TEAEs leading to discontinuation from study medication.
A total of 13 subjects (46.4 %) experienced adverse events that led to discontinuation of study drug.
Clinically, significant bleeding leading to discontinuation of antiplatelet therapy was used as an exclusion criterion.
Medication-related confusion led to discontinuation in 2/37 subjects during single-blind nabilone treatment.
